Ochre Bio completes SOC 2 Type 2 audit
The audit certifies effective security and data controls across platforms. It underscores commitment to protecting proprietary data and IP in pharma partnerships.
See the latest news and media coverage for Ochre. We track all announcements, press releases, and industry mentions in real time, all in one place.
Human-data-driven liver therapeutics developer
ochre-bio.comLast updated
In short: Ochre advanced its RNA liver disease therapies by opening a New York 'Liver ICU', securing $30M in funding, and partnering with GSK.
The audit certifies effective security and data controls across platforms. It underscores commitment to protecting proprietary data and IP in pharma partnerships.
Sarah brings over 15 years of experience in advancing therapies. She will lead operations across Oxford, New York, and Taipei teams.
Quin Wills and Jack Castle head to San Francisco next week to meet investors, collaborators, and partners. Interested parties can reach out to them.
The site features a large ex-vivo machine perfusion lab for late-stage validation and clinical trials. It honors team, partners, and organ donors.
Proceeds to support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set...
It could be the longest wait they'll ever know. Over 11,000 liver transplants were performed last year in the US, while thousands more patients remained...
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has opened a unique perfusion 'Liver...
Ochre Bio leased 5,894 square feet at Alexandria Real Estate Equities' Alexandria Center for Life Science at 430 East 29th Street.
Track Ochre and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ochre and other trending companies.